On Nov 09, major Wall Street analysts update their ratings for $Evolent Health (EVH.US)$, with price targets ranging from $27 to $63.
Barclays analyst Stephanie Davis maintains with a buy rating, and maintains the target price at $39.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and maintains the target price at $63.
Oppenheimer analyst Michael Wiederhorn maintains with a buy rating, and adjusts the target price from $45 to $34.
BTIG analyst David Larsen maintains with a buy rating, and adjusts the target price from $45 to $36.
JMP Securities analyst Constantine Davides maintains with a buy rating, and adjusts the target price from $43 to $27.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
Evolent Health's Q3 EBITDA was notably lower than the consensus, primarily due to a marked rise in Oncology costs, both retrospective and within the quarter. On a positive note, the company secured $200M in new run-rate business during Q3, underscoring the increased demand for specialty care management.
Evolent Health's Q3 outcomes were described as below expectations. Previously, it appeared that the company was on course to offset rising costs through contractual rate increases. Despite this, the recent stock selloff implies skepticism among investors about the company's ability to achieve approximately $300M in EBITDA. Nonetheless, the belief is that the recent circumstances are atypical and that Evolent's margins will return to normal as the rate increases are implemented.
Here are the latest investment ratings and price targets for $Evolent Health (EVH.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月9日，多家华尔街大行更新了$Evolent Health (EVH.US)$的评级，目标价介于27美元至63美元。
巴克莱银行分析师Stephanie Davis维持买入评级，维持目标价39美元。
TD Cowen分析师Charles Rhyee维持买入评级，维持目标价63美元。
奥本海默控股分析师Michael Wiederhorn维持买入评级，并将目标价从45美元下调至34美元。
BTIG分析师David Larsen维持买入评级，并将目标价从45美元下调至36美元。
JMP Securities分析师Constantine Davides维持买入评级，并将目标价从43美元下调至27美元。
此外，综合报道，$Evolent Health (EVH.US)$近期主要分析师观点如下：
evolent health的Q3 EBITDA明显低于共识，主要是由于肿瘤学成本显著上升，既包括回溯成本，也包括当季成本。值得一提的是，该公司在Q3期间获得了20000万美元的新业务运行率，突显了特殊护理管理需求的增加。
evolent health的Q3业绩被描述为低于预期。先前，公司似乎正在通过合同费率的提高来抵消成本上升。尽管如此，最近的股票抛售意味着投资者对该公司实现大约30000万美元的EBITDA能力持怀疑态度。尽管如此，人们认为最近的情况是不寻常的，并且随着费率的实施，evolent health的利润率将恢复正常。
以下为今日5位分析师对$Evolent Health (EVH.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
